和胃降逆法治疗胃食管反流性咳嗽临床观察

目的:观察和胃降逆法治疗胃食管反流性咳嗽的临床疗效。方法:将120例胃食管反流性咳嗽患者,随机分为治疗组和对照组各60例。治疗组在常规治疗基础上服用和胃止嗽汤,对照组在常规治疗基础上加用兰索拉唑及枸橼酸莫沙必利分散片。两组患者均治疗4个疗程。结果:治疗结束后,治疗组总有效率为86.67%(95%CI=78.07%~95.27%),对照组为71.67%(95%CI=60.27%~83.07%),两组综合疗效比较(u=2.777 7,P=0.007 5),差异有显著性意义;两组治疗后及随访半年(ITT分析),咳嗽症状、RDQ、LCQ积分比较(P0.05或P0.01),差异有显著性意义;治疗后,治疗组不良反应发生率为10.00%(95%CI=6.28%~13.72%),对照组为26.67%(95%CI=15.48%~37.86%),两组比较(χ~2=5.565 9,P=0.020 0),差异有显著性意义;治疗后随访半年(ITT分析),治疗组复发率为23.33%(95%CI=12.69%~34.02%),对照组为41.67%(95%CI=29.20%~53.91%),两组比较(χ~2=4.596 4,P=0.034 0),差异有显著性意义。结论:治疗组临床疗效优于对照组的证据可靠,其收益为OR=0.39(95%CI=0.15~0.99),NNT=7(95%CI=3.39~212.77)。且两组不良反应发生率、复发率OR的95%CI值均1。

Clinical Observation of Harmonizing Stomach for Descending Adverse Qi on Cough due to Gastroesophageal Reflux

Objective ： To observe the clinical curative effect of harmonizing stomach for descending adverse Qi on cough due to gastroesophageal reflux. Method： 120 patients with cough due to gastroesophageal reflux were randomly divided into a treatment group and a control group, each group with 60 cases： On the basis of conventional therapy, the treatment group took the hewei zhisou decoction, the control group was received Lansoprazole and Mosapride Acid Citrate Edge tablets. Two groups of patients were treated for 4 courses. Results ： After the treatment, the total effective rate of treatment group was 86.67% （95% CI = 78.07% -95.27% ）, while the control group 71.67% （95 % CI = 60. 27% -83.07% ） , Comprehensively compared the efficacy of the two groups （u = 2. 777 7, P = 0. 007 5 ） there were significant differences. After treatment and follow-up six months of two groups（ ITY analysis）, in cough symptom,RDQ,LCQ integral comparison （P 〈 0. 05 or P 〈 0. 01 ）, there were significant differences ; after treatment, the incidence of adverse reactions of treatment group was 10.00% （95 % CI = 6.28 % - 13. 72% ）, while the control group 26.67% （95% CI = 5.48% - 37.86% ）, compared two groups（χ^2 = 5. 565 9, P = 0. 020 0）, there were significant differences; after treatment and follow-up six months （ITF analysis） the relapse rate of treatment group was 23.33% （95% CI = 12. 69% -34.02% ）, while the control group 41.67% （95% CI = 29.20% - 53.91% ）, compared two groups （χ^2 = 4. 596 4, P = 0.034 0 ）, there were significant differences. Conclusion： The evidence, that the clinical efficacy of the treatment group was better than of the control group is reliable, Its benefit was OR = 0. 39 （95 % CI = 0. 15 - 0. 99 ）, NNT = 7 （95 % CI = 3.39 - 212.77 ）. And 95 % C I values of the incidence of adverse reactions and the recurrence rate OR in two groups were 〈 1.